M3(R2)Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals: Questions and Answers
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
March 13, 2013
April 24, 2020
04bea7cb-30a1-49e6-94c9-51131e6004d7
Related Documents
Postmarketing Studies and Clinical Trials—Implementation of Section 505(o)(3) of the Federal Food, Drug, and Cosmetic Act Guidance for Industry
Guidance DocumentApril 12, 2011Center for Drug Evaluation and Research
S1C(R2) Dose Selection for Carcinogenicity Studies of Pharmaceuticals
Guidance DocumentSeptember 17, 2008Center for Drug Evaluation and Research
M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals
Guidance DocumentJanuary 21, 2010Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust KeyPedia for their regulatory compliance needs.